Skip to main content
SpringerLink
Log in

Is rituximab effective as a single agent in mantle-cell lymphoma?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Grillo-López AJ (2004) The ODAC chronicles: Part II. Statistics and clinical medicine in the USA—the triumph of science over art? Expert Rev Anticancer Ther 4: 941–944

    Article  Google Scholar 

  2. Howard O et al. (2002) Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. J Clin Oncol 20: 1288–1294

    Article  CAS  Google Scholar 

  3. Demidem A et al. (1997) Chimeric antiCD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12: 177–185

    Article  CAS  Google Scholar 

  4. Dreyling MH et al. (2003) Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma—final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood 102 (Suppl): a351

    Google Scholar 

  5. Lenz G et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–1992

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Chairman of the Neoplastic Diseases Research Institute, Rancho Santa Fé, CA, USA

    Antonio J Grillo-López

Authors
  1. Antonio J Grillo-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grillo-López, A. Is rituximab effective as a single agent in mantle-cell lymphoma?. Nat Rev Clin Oncol 2, 500–501 (2005). https://doi.org/10.1038/ncponc0297

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0297

  • Springer Nature Limited

Search

Navigation